Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medclair ABNGM:MCLR -2.24%70 Altman Z2-Score is 11.34 as of Jul. 15, 2026, which is 70% above its 10-year median of 6.67. GuruFocus rates NGM:MCLR with a GF Score™ of 70/100 and a GF Value™ of kr2.35 (Modestly Overvalued). Among 843 Medical Devices & Instruments companies, Medclair AB ranks better than 87.07% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Good Sign:
Medclair AB has a Altman Z2-Score of 11.34, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for Medclair AB's Altman Z2-Score or its related term are showing as below:
NGM:MCLR'
s Altman Z2-Score Range Over the Past 10 Years
Min: -6.3 Med: 6.67 Max: 12.46
Current: 11.34
During the past 11 years, Medclair AB's highest Altman Z2-Score was 12.46. The lowest was -6.30. And the median was 6.67.
Medclair AB (NGM:MCLR) Altman Z2-Score Explanation
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
Altman Z2-Score does not apply to financial companies.
Medclair AB Altman Z2-Score Related Terms
Medclair AB Altman Z2-Score Historical Data
* Premium members only.
The historical data trend for Medclair AB's Altman Z2-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:MCLR vs ABT, SYK, MDT: Altman Z2-Score Comparison
For the Medical Devices subindustry, Medclair AB's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medclair AB Altman Z2-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medclair AB's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where Medclair AB's Altman Z2-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
Medclair AB's Altman Z2-Score for today is calculated with this formula:
Z
=
6.56
*
X1
+
3.26
*
X2
+
6.72
*
X3
+
1.05
*
X4_2
=
6.56
*
0.4443
+
3.26
*
0
+
6.72
*
0.0555
+
1.05
*
7.6722
=
11.34
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
Medclair AB (NGM:MCLR) has a Altman Z2-Score of 11.34 as of Jul. 15, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Medclair AB and its competitors. This is 70% above median its historical median of 6.67. According to the industry distribution chart, Medclair AB ranks #109 out of 843 companies in the Medical Devices & Instruments industry, placing it in the top 12.9%.
Is Medclair AB's Altman Z2-Score too high?
Medclair AB's current Altman Z2-Score of 11.34 is 70% above median its 10-year median of 6.67. The Medical Devices & Instruments industry median Altman Z2-Score is 3.49. Medclair AB's value of 11.34 is 224.9% above this industry median. Based on the distribution chart, Medclair AB ranks #109 out of 843 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medclair AB has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medclair AB's Altman Z2-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medclair AB ranks #109 out of 843 companies for Altman Z2-Score. This places Medclair AB in the top 13% of its industry — outperforming the majority of peers. The industry median Altman Z2-Score is 3.49. Medclair AB's value of 11.34 is 224.9% above this benchmark. While the company's 10-year median is 6.67 vs. the industry median of 3.49, Medclair AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Medical Devices & Instruments company?
The median Altman Z2-Score among Medical Devices & Instruments companies is 3.49, based on 843 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medclair AB's current Altman Z2-Score of 11.34 is 224.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Medclair AB and its competitors. For the Medical Devices & Instruments industry, the median Altman Z2-Score is 3.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medclair AB's current Altman Z2-Score is 11.34, which is 70% above median its own 10-year median of 6.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medclair AB stock overvalued right now?
Based on GuruFocus' analysis, Medclair AB (NGM:MCLR) is currently considered Modestly Overvalued. The stock's GF Value™ is kr2.35, compared to a current price of kr3.05 — trading 29.8% above its estimated fair value. The current Altman Z2-Score is 11.34, which is 70% above median its 10-year median of 6.67 and 224.9% above the Medical Devices & Instruments industry median of 3.49. Medclair AB's overall GF Score™ is 70/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Medclair AB (NGM:MCLR), the current Altman Z2-Score is 11.34 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medclair AB (NGM:MCLR) Overvalued in 2026?
Based on GuruFocus' analysis, Medclair AB stock appears to be overvalued.
The current stock price of kr3.05 is trading 29.8% above its estimated GF Value™ of kr2.35.
GuruFocus considers Medclair AB to be Modestly Overvalued.
Key valuation signals for NGM:MCLR:
Altman Z2-Score: 11.34 (70% above median its 10-year median of 6.67)
GF Value™: kr2.35 vs. price of kr3.05 (29.8% above fair value)
Industry Position: 224.9% above the Medical Devices & Instruments median (#109 of 843)
No single metric tells the full story. See the NGM:MCLR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medclair AB operates in healthcare industry. The company has two units: Central Destruction Unit (CDU) and Mobile Destruction Unit (MDU) decomposes the nitrous oxide entering the unit, transforming it to nitrogen (N2) och oxygen (O2). It also provide solutions for various N2O methods such as double mask, single mask, mouthpiece, or free flow, which ensures a safe work environment for healthcare professionals.
70GF Score
Get the complete analysis for NGM:MCLR
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:MCLR has been successfully added to your 
